Business Context and Reporting Period
This Form 6-K filing by AC Immune SA covers the month of January 2019. The report confirms the effective date of a previously disclosed license and collaboration agreement with Eli Lilly and Company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a notification of a corporate event rather than a financial performance report.
Material Changes
The primary material change is the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 at 11:59 p.m. EST on January 22, 2019. Consequently, all conditions to effectiveness were met, and the License Agreement with Eli Lilly and Company became effective on January 23, 2019.
Outlook, Risks, and Management Commentary
Management notes that the agreement was subject to customary antitrust review, which has now concluded. The filing incorporates this report by reference into specific registration statements (Form F-3 and Form S-8). No specific financial guidance, new risks, or unusual items are detailed in this text beyond the successful closing of the regulatory review.
Investor Verification Checklist
- Verify the terms of the License Agreement as described in the Form 6-K filed on December 12, 2018.
- Confirm the effective date of the collaboration with Eli Lilly and Company is January 23, 2019.
- Review the referenced registration statements (333-224694, 333-227016, and 333-216539) for updated disclosures.